Core Insights - BioStem Technologies has launched a new product line, American Amnion, aimed at enhancing wound care for veterans, showcasing its commitment to serving this underserved population [1][3][6] Product Overview - American Amnion and American Amnion AC are placental-derived allografts designed to improve chronic wound healing through enhanced structural integrity and cell preservation [2][4] - American Amnion AC consists of full thickness dehydrated human amnion and chorion membrane, while American Amnion is made from dehydrated human amnion membrane, both utilizing BioStem's proprietary BioRetain technology [4] Clinical Performance - Clinical studies indicate that allografts produced with BioRetain technology show superior performance, with a 53% probability of wound closure compared to 31% for standard care [5] - The BioRetain-preserved DHACM demonstrated a 14% reduction in time to closure and required 27% fewer applications than a leading competitor [5] Market Context - The use of placental-based products in the VA system has increased by 50% over the last five years, highlighting a growing demand for advanced wound care solutions [6] - The introduction of American Amnion is positioned as a significant advancement in the standard of care for veterans with chronic, non-healing wounds [6] Community Engagement - BioStem Technologies is actively involved in community support, exemplified by its sponsorship of the Florida Panthers' Heroes Among Us program, which honors military veterans [7] Company Background - BioStem Technologies specializes in placental-derived biologics for advanced wound care, focusing on innovative solutions that leverage the natural properties of perinatal tissue [8] - The company’s products are processed at an FDA registered and AATB accredited facility in Pompano Beach, Florida, ensuring compliance with industry standards [8]

Core Insights - BioStem Technologies, Inc. has announced the inclusion of its products VENDAJE and VENDAJE AC in Florida Medicaid's list of covered skin substitutes, marking a significant milestone in its national reimbursement strategy [1][2][3] Group 1: Company Developments - The addition of Florida Medicaid coverage enhances BioStem's mission to provide high-quality wound care, significantly increasing its addressable patient base in one of the largest Medicaid markets in the U.S. [3] - BioStem's advanced wound care market is estimated to exceed $11 billion annually in the U.S., with over 70 million Americans enrolled in Medicaid, including approximately 7 million aged 65 and older [3] Group 2: Product Information - VENDAJE and VENDAJE AC are placental-derived, minimally manipulated dehydrated tissue allografts designed for soft tissue wound protection, utilizing the proprietary BioREtain technology to optimize the retention of extracellular matrix scaffolding [5][6] Group 3: Distribution Strategy - BioStem is actively seeking qualified regional distributors and wound care organizations to represent the VENDAJE portfolio in Florida and other covered states [4]